| Literature DB >> 29849634 |
Takahiro Hokari1, Toshiya Morozumi1, Yasutaka Komatsu1, Taro Shimizu1,2, Toshiaki Yoshino3, Maki Tanaka3, Yoshie Tanaka3, Kaname Nohno4, Takehiko Kubota1, Hiromasa Yoshie1.
Abstract
OBJECTIVE: We evaluated the efficacies of antimicrobial photodynamic therapy (aPDT) and minocycline ointment (MO) on clinical and bacteriological markers and the local host inflammatory response.Entities:
Year: 2018 PMID: 29849634 PMCID: PMC5907519 DOI: 10.1155/2018/1748584
Source DB: PubMed Journal: Int J Dent ISSN: 1687-8728
Figure 1Flowchart of the study from enrollment to completion of the trial.
Subject demographics and periodontal data from full-mouth locations at baseline.
| aPDT group ( | MO group ( | |
|---|---|---|
| Gender (male/female) | 7/8 | 6/9 |
| Age (years) | 61.4 ± 10.2 | 66.7 ± 9.5 |
| Number of teeth ( | 23.3 ± 3.7 | 24.5 ± 3.6 |
| Bone resorption (%) | 24.3 ± 7.0 | 28.3 ± 9.6 |
| PlI | 0.4 ± 0.7 | 0.5 ± 0.6 |
| GI | 0.9 ± 0.7 | 1.0 ± 0.6 |
| PD (mm) | 3.0 ± 0.9 | 2.9 ± 0.8 |
| CAL (mm) | 3.8 ± 1.1 | 3.7 ± 1.2 |
| BOP (% positive) | 27.1 ± 16.5 | 28.6 ± 15.7 |
Values are represented as mean ± standard deviation. Gender: Fisher's exact test (P < 0.05). Other parameters: Mann–Whitney U test (P < 0.05).
Changes in clinical parameters and bacterial levels after aPDT or local minocycline administration.
| (a) Baseline | (b) 1 week after treatment | (c) 4 weeks after treatment |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Between (a) and (b) | Between (a) and (c) | Between aPDT and MO groups | |||||||||||
| aPDT group | MO group | aPDT group | MO group | aPDT group | MO group | aPDT group | MO group | aPDT group | MO group | (a) | (b) | (c) | |
| PD-treated sites (mm) | 5.8 ± 1.0 | 5.4 ± 1.1 | 5.4 ± 1.3 | 4.7 ± 1.3 | 4.8 ± 1.4 | 4.3 ± 1.4 | 0.0569 | 0.0024† | 0.0003† | 0.0001† | 0.1417 | 0.045∗ | 0.1581 |
| CAL-treated sites (mm) | 6.8 ± 1.6 | 6.1 ± 1.8 | 6.2 ± 1.8 | 5.4 ± 1.6 | 5.8 ± 1.8 | 5.1 ± 1.7 | 0.0254 | 0.004† | 0.0005† | 0.0022† | 0.1809 | 0.1275 | 0.2443 |
| BOP-treated sites (% positive) | 76.7 ± 43.0 | 80.0 ± 40.7 | 66.7 ± 47.9 | 43.3 ± 50.4 | 40.0 ± 49.8 | 46.7 ± 50.7 | 0.4054 | 0.0023† | 0.0116† | 0.0039† | 0.756 | 0.0717 | 0.6054 |
| Total bacteria (log10) | 4.72 ± 1.05 | 4.53 ± 0.87 | 4.68 ± 0.76 | 4.16 ± 0.53 | 4.57 ± 1.11 | 4.17 ± 0.67 | 0.8015 | 0.1228 | 0.4771 | 0.2101 | 0.3826 | 0.0531 | 0.0805 |
|
| 2.63 ± 1.62 | 2.68 ± 1.44 | 2.42 ± 1.68 | 0.61 ± 0.41 | 2.28 ± 1.79 | 1.12 ± 1.31 | 0.8753 | 0.0033† | 0.3574 | 0.0053† | 0.9331 | 0.0006∗ | 0.0548 |
|
| 2.70 ± 3.47 | 5.80 ± 12.11 | 3.59 ± 4.39 | 0.01 ± 0.02 | 3.20 ± 4.48 | 1.20 ± 3.49 | 0.4328 | 0.0022† | 0.7213 | 0.0414 | 0.6153 | 0.0006∗ | 0.0518 |
|
| 3.01 ± 1.50 | 2.89 ± 1.31 | 2.89 ± 1.54 | 1.45 ± 0.87 | 2.87 ± 1.51 | 2.03 ± 1.23 | 0.7986 | 0.0032† | 0.5627 | 0.064 | 0.5883 | 0.0088∗ | 0.0915 |
|
| 4.08 ± 3.58 | 4.27 ± 4.60 | 4.75 ± 4.62 | 0.77 ± 1.03 | 4.51 ± 4.30 | 2.62 ± 4.70 | 0.7537 | 0.0019† | 0.7532 | 0.2719 | 0.9834 | 0.0083∗ | 0.1694 |
Data are presented as mean ± standard deviation. Ratio was defined as (individual bacteria count)/(total bacterial count). Intergroup comparison between groups: Mann–Whitney U test (∗P < 0.05). Intragroup comparisons: Wilcoxon signed-rank test with the Bonferroni correction for multiple comparisons (†P < 0.017).
Figure 2Changes in IL-1β, IL-2, IL-4, IL-5, IL-6, IL-12p70, IL-13, IFN-γ, TNF-α, and GM-CSF levels in gingival crevicular fluid in the aPDT (a) and MO (b) groups. Results are shown as mean ± standard deviation. Data were adjusted for multiple comparisons. ∗Significant changes at P < 0.017. IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; aPDT, antimicrobial photodynamic therapy; MO, minocycline ointment.